← Leaderboards
Karen Bell
Columbia University Health Sciences
$1,220,572
Attributed
$1,220,572
Total exposure
10
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,220,572 · 10
By mechanism
M01$1,220,572 · 10
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Henry N Ginsberg$119,772,603
- Steven M Kawut$28,347,465
- Randolph S Marshall$10,866,382
- Ethel Siris$749,324
- Stuart D Katz$171,255,562
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectAlzheimer'S DiseaseHuman Therapy EvaluationCognitionDrug Screening /EvaluationHuman Old Age (65+)Cognition DisordersBrain Disorder ChemotherapyEstrogensFemaleHuman Middle Age (35-64)Functional AbilityHormone TherapyMental Disorder PreventionWomen'S HealthMental Disorder ChemotherapyPlacebosDrug /AgentCarnitinePatient Oriented ResearchClinical TrialsApolipoprotein EChemoprevention
Grant awards (26)
HOMOCYSTEINE IN ALZHEIMER'S DISEASE$13,548
M01 · FY2005 · RR
ALZHEIMER'S DISEASE PREVENTION TRIAL WITH ESTROGEN$12,580
M01 · FY2005 · RR
PREVENTION INSTRUMENT PROTOCOL$7,096
M01 · FY2005 · RR
SIMVASTATIN AND ALZHEIMER'S DISEASE$2,903
M01 · FY2005 · RR
AGITATION AND PSYCHOSIS IN DEMENTIA AND PARKINSONISM$322
M01 · FY2005 · RR
Alzheimer's Disease Prevention Trial with Estrogen$11,387
M01 · FY2004 · RR
Prevention Instrument Protocol$10,831
M01 · FY2004 · RR
Executive Functions Study$2,222
M01 · FY2004 · RR
Aricept/Vitamin E MCI Trial$1,111
M01 · FY2004 · RR
Homocysteine$556
M01 · FY2004 · RR
STATIN$556
M01 · FY2004 · RR
ESTROGEN REPLACEMENT THERAPY IN PATIENTS WITH ALZHEIMERS DISEASE$192,910
M01 · FY2002 · RR
ACETYL L CARNITINE IN PATIENT BETWEEN 45-60 YEARS WITH ALZHEIMERS DISEASE$192,910
M01 · FY2002 · RR
MK 0966 FOR TREATMENT OF MILD COGNITIVE IMPAIR &PREVENT OF CONVERSIO$192,910
M01 · FY2002 · RR
ACETYL L CARNITINE IN PATIENT BETWEEN 45-60 YEARS WITH ALZHEIMERS DISEASE$192,910
M01 · FY2001 · RR
MK 0966 FOR TREATMENT OF MILD COGNITIVE IMPAIR &PREVENT OF CONVERSIO$192,910
M01 · FY2001 · RR
ESTROGEN REPLACEMENT THERAPY IN PATIENTS WITH ALZHEIMERS DISEASE$192,910
M01 · FY2001 · RR
MK 0966 FOR TREATMENT OF MILD COGNITIVE IMPAIR &PREVENT OF CONVERSIO$0
M01 · FY2001 · RR
ESTROGEN REPLACEMENT THERAPY IN PATIENTS WITH ALZHEIMERS DISEASE$0
M01 · FY2001 · RR
ACETYL L CARNITINE IN PATIENT BETWEEN 45-60 YEARS WITH ALZHEIMERS DISEASE$0
M01 · FY2001 · RR
ACETYL L CARNITINE IN PATIENT BETWEEN 45-60 YEARS WITH ALZHEIMERS DISEASE$0
M01 · FY2000 · RR
MK 0966 FOR TREATMENT OF MILD COGNITIVE IMPAIR &PREVENT OF CONVERSIO$0
M01 · FY2000 · RR
MK 0966 FOR TREATMENT OF MILD COGNITIVE IMPAIR &PREVENT OF CONVERSIO$0
M01 · FY2000 · RR
ESTROGEN REPLACEMENT THERAPY IN PATIENTS WITH ALZHEIMERS DISEASE$0
M01 · FY2000 · RR
ESTROGEN REPLACEMENT THERAPY IN PATIENTS WITH ALZHEIMERS DISEASE$0
M01 · FY2000 · RR
ACETYL L CARNITINE IN PATIENT BETWEEN 45-60 YEARS WITH ALZHEIMERS DISEASE$0
M01 · FY2000 · RR